AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Altimmune, Inc.
Video analysis: ALT
All videosNo video analysis for this stock yet. Request one from our team.
News: ALT
Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?
Altimmune (ALT) reported earnings 30 days ago. What's next for the stock?
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAMPR NewswireNEW YORK, Sept. 10, 2026NEW YORK, Sept.
Alpha Liquid Terminal Relaunches as the ALT/X Compute Terminal, Pivoting to GPU Pricing, Power and AI Infrastructure Market Data
New York, NY, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Alpha AI Corporation ("Alpha AI"), developer of the Alpha Liquid Terminal ("ALTx"), today announced the relaunch of its platform as the ALT/X Compute Terminal , refocusing the product on pricing, power and capacity data for the global AI compute market.
Bank of America Corp DE Raises Position in Altimmune, Inc. $ALT
Bank of America Corp DE boosted its position in shares of Altimmune, Inc. (NASDAQ: ALT) by 48.6% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 570,203 shares of the company's stock after buying an additional 186,420 shares during the quarter. Bank of
Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference
GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10, 2026, at 9:30 a.m. ET.
Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Rating of “Moderate Buy” from Analysts
Shares of Altimmune, Inc. (NASDAQ: ALT - Get Free Report) have been given a consensus rating of "Moderate Buy" by the nine brokerages that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy
Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus
ALT has moved pemvidutide into Phase III MASH testing, with supportive mid-stage data, regulatory backing and a 2029 readout ahead.
Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?
ALT's stronger cash position supports pemvidutide's MASH, AUD and ALD programs, but long timelines, funding needs and competition remain risks.
